艾迪注射液联合一线化疗方案治疗非小细胞肺癌临床疗效的Meta分析

发布时间：2018-03-18 02:30

本文选题：艾迪注射液　切入点：非小细胞肺癌　出处：《中成药》2017年06期 　论文类型：期刊论文

【摘要】：目的通过收集艾迪注射液联合一线化疗用于非小细胞肺癌的随机对照试验研究并进行系统评价,评价艾迪注射液辅助治疗非小细胞肺癌的疗效。方法检索Pubmed、知网、万方、维普数据库,检索时间由建库至至2015年3月,获取艾迪注射液联合含铂类一线化疗治疗非小细胞肺癌的RCT研究文献。按照纳入、排除标准筛选文献,采用改良的Jadad量表进行质量评价,Meta分析使用Cochrane网Rev Man5.3软件进行。结果纳入9项随机对照试验研究,共计1 207个病例。Meta分析结果:和单用化疗组相比,艾迪联合化疗组能提高治疗有效率(OR=1.28,95%CI1.01~1.62,P=0.04);改善生存质量(OR=2.63,95%CI 1.78~3.88,P0.000 01);降低胃肠道反应的发生率(OR=0.52,95%CI 0.35~0.78,P=0.001)。联合组在降低血红蛋白下降的发生率方面可能优于对照组,但差异无统计学意义(OR=0.73,95%CI 0.43~1.24,P=0.24);在白细胞下降发生率方面联合组是否优于单纯化疗组尚需存疑(OR=0.51,95%CI 0.26~1.00,P=0.05)。结论艾迪注射液治疗非小细胞肺癌在提高治疗有效率、改善生存质量和减轻胃肠道反应方面具有一定的疗效;可能能够减少化疗患者血红蛋白下降发生率,但由于差异不具有统计学意义,结论仍有待验证;艾迪注射液能否减少化疗患者白细胞下降发生率仍需存疑。
[Abstract]:Objective to evaluate the efficacy of Adi injection in the treatment of non-small cell lung cancer (NSCLC) by collecting Aidi injection combined with first-line chemotherapy in a randomized controlled trial and to evaluate the efficacy of Adi injection in the treatment of NSCLC. Wiper database, from the establishment of the database to March 2015, to obtain Aidi injection in combination with platinum-containing first-line chemotherapy for non-small cell lung cancer RCT research literature, according to the inclusion, exclusion criteria for screening literature, The modified Jadad scale was used for quality evaluation and meta-analysis was performed with Cochrane net Rev Man5.3 software. Results in 9 randomized controlled trial studies, a total of 1 207 cases. Meta-analysis results: compared with chemotherapy alone group. The Aidi combined chemotherapy group could improve the effective rate of the treatment, the effective rate was 1.28995 CI 1.01and 1.62P0.04; the improvement of quality of life was 2.6395CI 1.783.88P0.00001; and the incidence of gastrointestinal reaction was decreased by 0.350.350.78P0.0010.The combined group may be superior to the control group in decreasing the incidence of hemoglobin reduction. However, there was no significant difference in the incidence of leukocytopenia between the combined group and the chemotherapy group. Conclusion the efficacy of Aidi injection in the treatment of non-small cell lung cancer is better than that in the chemotherapy alone group, but there is no significant difference between the two groups in the incidence of leukocytopenia, and whether the combined group is superior to the chemotherapy group in the incidence of leukocytopenia. Conclusion the therapeutic efficacy of Aidi injection in the treatment of non-small cell lung cancer is higher than that in the chemotherapy group. Improving the quality of life and alleviating gastrointestinal reaction may reduce the incidence of hemoglobin reduction in chemotherapy patients, but the difference is not statistically significant, the conclusion remains to be verified. Whether Aidi injection can reduce the incidence of leukopenia in chemotherapeutic patients remains doubtful.
【作者单位】：广州中医药大学;广州中医药大学第一附属医院;
【基金】：国家自然科学基金青年基金项目(81403227)
【分类号】：R734.2

【相似文献】